An august gathering of representatives of organizations occupying the Sickle Cell Disease/Inherited Blood Disorders space in Nigeria took place at the National Sickle Cell Centre, Idi Araba, Lagos on February 20 2023. The meeting, which held in-person and virtually was one of the many coalition-building meetings of the Global Action Network for Sickle Cell Disease and other Inherited Blood Disorders (GANSID)- a newly established entity aiming to raise the profile of inherited blood disorders.
Addressing the gathering, GANSID’s CEO, Mrs. Lanre Tunji-Ajayi, M.S.M, described the world as a global village where people and organizations can and should connect with one another. Mrs. Tunji-Ajayi espoused a vision of GANSID empowering the organizations serving the Sickle Cell Disease and other Inherited Blood Disorders organizations wherever they may be in the world and the impact of this action to be felt by the constituent individual members.
In attendance at the meeting were Consultant Public Health Physician and National Director/CEO, Sickle Cell Foundation (Nigeria) Dr. Annette Akinsete, Professor Adeyemo, an SCD/Hemophilia consultant at the College of Medicine University of Lagos (representing the Nigerian Society of Haematology and Blood Transfusion) as well as Dr. Enitan Ademuson, representing the Nigerian Heart Foundation. Among others present were Mrs. Doris Gbemiloye, of Genotype Foundation, Elder John Owhighogho Arure, of Success Sickle Cell Foundation and Ms Toyin Adesola, Chair, Coalition of SCD Non-Governmental Organizations and Dr. Babatunde Kuteyi, representing the SCD Stakeholders of Federal Medical Centre, Ebute Meta.
Joining the meeting virtually were, among many other participants, Professor Adekunle Adekile from Kuwait University, Professor Adeyinka Falusi, Founder/CEO, Sickle Cell Hope Alive Foundation (SCHAF) from the United States, Dr. Alayo Sopekan from the Federal Ministry of Health and Mrs. Megan Adediran, CEO, Hemophilia Foundation of Nigeria.
The GANSID will be formally launched in April 2023.